SELLAS Life Sciences (SLS) Research & Development (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Research & Development of $5.1 million for Q1 2026, up 60.03% year-over-year from $3.2 million in Q1 2025, and up 8.44% quarter-over-quarter from $4.7 million in Q4 2025.
SELLAS Life Sciences (SLS) Research & Development (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Research & Development for 17 consecutive years, with $5.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 60.03% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $17.9 million (up 4.4% YoY), while the FY2025 annual figure was $16.0 million, down 16.1% from the prior year.
- Research & Development climbed to $5.1 million in Q1 2026 per SLS's latest filing, from $4.7 million in the prior quarter.
- Across five years, Research & Development topped out at $7.2 million in Q1 2023 and bottomed at $3.2 million in Q1 2025.
- Historically, Research & Development has averaged $5.0 million across 5 years, with a median of $5.1 million in 2023.
- Annual changes were most pronounced in 2022 — Research & Development surged 72.3% — and 2025, when it slumped 37.29%.
- SELLAS Life Sciences' Research & Development stood at $5.8 million in 2022, then dropped by 12.81% to $5.1 million in 2023, then fell by 12.95% to $4.4 million in 2024, then rose by 6.6% to $4.7 million in 2025, then gained by 8.44% to $5.1 million in 2026.
- Business Quant data shows SLS's Research & Development at $5.1 million in Q1 2026, $4.7 million in Q4 2025, and $4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | 6.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.27 Mn |
| Mar 31, 2026 | 5.13 Mn |
| Dec 31, 2025 | 4.73 Mn |
| Sep 30, 2025 | 4.22 Mn |
| Jun 30, 2025 | 3.87 Mn |
| Mar 31, 2025 | 3.21 Mn |
| Dec 31, 2024 | 4.44 Mn |
| Sep 30, 2024 | 4.36 Mn |
| Jun 30, 2024 | 5.19 Mn |
| Mar 31, 2024 | 5.11 Mn |
| Dec 31, 2023 | 5.10 Mn |
| Sep 30, 2023 | 5.81 Mn |
| Jun 30, 2023 | 5.92 Mn |
| Mar 31, 2023 | 7.17 Mn |
| Dec 31, 2022 | 5.85 Mn |
| Sep 30, 2022 | 4.28 Mn |
| Jun 30, 2022 | 5.53 Mn |
| Mar 31, 2022 | 4.61 Mn |
| Dec 31, 2021 | 3.39 Mn |
| Sep 30, 2021 | 4.54 Mn |